Evaluation of Humoral Response of Emergency Unit Healthcare Workers after Third Dose of COVID-19 Vaccination

Abror Irsan, Mardhia Mardhia, Ambar Rialita


Background:  Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is an emerging disease that has become pandemic. Healthcare workers are vulnerable persons due to SARS-CoV-2 infection. Healthcare workers are a government priority in the COVID-19 vaccine program. Antibody titer evaluation to healthcare workers as the first liner is essential due to the risk of the job. Purposes: The study aims to assess IgG antibody humoral response in healthcare workers in the emergency unit of Anton Soedjarwo Hospital, Pontianak, before and after the third dose of the COVID-19 vaccine. Methods: This study was a descriptive study with a cohort method. Twenty-two healthcare workers in the Emergency Unit in Anton Soedjarwo Hospital, Pontianak, participated in the study. Three ml venous blood samples were collected from the participants in two periods to quantify IgG antibody titer. The first period was before the third dose of the COVID-19 vaccine, and the second period was one month after the third dose of the COVID-19 vaccine. Chemiluminescent Microparticle Immunoassay (CMIA) methods were used to quantification IgG antibodies against spike-receptor binding domain (S-RBD) protein of SARS-CoV-2 Results: One month before the third dose of the COVID-19 vaccine, the majority of IgG antibodies show seropositivity (90.91%), with most on range 50-10,000 AU/ml (54.55%). Two participants (9.09%) show IgG antibodies less than 50 AU/ml (seronegative). One month after the third vaccination dose, all participants (100%) elicit IgG antibodies. Based on the comparison of IgG antibody titer before and after the third dose of the vaccine, the majority (68.18%) showed increasing the IgG antibody titer after the third vaccine.  Conclusion: The third dose vaccine might effectively elevate immune response to SARS-CoV-2 infection.


COVID-19; COVID-19 Vaccine; humoral response; IgG antibody titer

Full Text:



Ing EB, Xu QA, Salimi A, Torun N. Physician deaths from corona virus (COVID-19) disease. Occup Med (Chic Ill). 2020;70(5):370–4.

Bayram A, Demirbakan H, Karadeniz PG, Erdoğan M, Koçer I. Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021;93(9):5560–7.

Syaifuddin AI. Over a dozen vaccinated doctors dead as Indonesia ’ s virus cases surge [Internet]. 2021. p. 1–2. Available from: https://medicalxpress.com/ news/2021-06-dozen-vaccinated-doctors-dead-indonesia.html

Iyengar KP, Ish P, Kumar G, Malhotra N. COVID-19 and mortality in doctors. Diabetes Metab Syndr. 2020;14:1743–6.

Uysal EB, Gümüş S, Bektöre B, Bozkurt H, Gözalan A. Evaluation of antibody response after COVID-19 vaccination of healthcare workers. J Med Virol. 2022; 94(3):1060–6.

Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020Oct;20(10): 615–32.

Mahendradhata Y, Andayani NLPE, Hasri ET, Arifi MD, Siahaan RGM, Solikha DA, et al. The Capacity of the Indonesian Healthcare System to Respond to COVID-19. Front Public Heal. 2021;9:1–9.

Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. Front Immunol. 2021;12:1–12.

Yoo JH. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021. J Korean Med Sci. 2021;36(6):1–17.

Tanis J, Vancutsem E, Piérard D, Weets I, Bjerke M, Schiettecatte J, et al. Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays. Diagn Microbiol Infect Dis. 2021;100(1).

English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG. Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new variants of concern, VOC 202012/v1 (United Kingdom) and VOC 202012/v2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods. J Clin Microbiol. 2021;59(9):1–10.

Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol. 2020;58(8):4–11.

Manalac J, Yee J, Calayag K, Nguyen L, Patel PM, Zhou D, et al. Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab. Clin Chim Acta. 2020;510:687–90.

Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA - J Am Med Assoc. 2021;326(1):35–45.

Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385(10):875–84.

Peng P, Deng H jun, Hu J, Wei X yu, Xue J jiang, Li T ting, et al. Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine. Cell Discov. 2021;7(1):10–3.

Azak E, Karadenizili A, Uzuner H, Karakaya N, Canturk NZ, Hulagu S. Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection. Int J Infect Dis. 2021;113:58–64.

Murin CD, Wilson IA, Ward AB, Biology C, Jolla L, Discovery I, et al. Antibody responses to viral infections: a structural perspective across three different enveloped viruses Charles. Nat Microbiol. 2019;4(5):734–47.

Banga Ndzouboukou JL, Zhang Y di, Lei Q, Lin X song, Yao Z jie, Fu H, et al. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. Curr Med Sci. 2021;1–8.

Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (80- ). 2021;371(6529):1–14.

Kučinskaitė-Kodzė I, Simanavičius M, Šimaitis A, Žvirblienė A. Persistence of SARS-CoV-2-specific antibodies for 13 months after infection. Viruses. 2021;13 (11).

Syahniar R, Purba MB, Bekti HS, Mardhia M. Vaccines against Coronavirus Disease : Target Proteins , Immune Responses , and Status of Ongoing Clinical Trials. J Pure Appl Microbiol. 2020;14(4):2253–63.

Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021;384(23):2259–61.

Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393–400.

Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019;32(2).

DOI: https://doi.org/10.24853/mmj.3.1.27-32


  • There are currently no refbacks.

Indexed by:



Lisensi Creative Commons

Work is distributed under the Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright of Muhammadiyah Medical Journal (e issn: 2721-317X)

Powered by Puskom-UMJ